In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 30, No. 15_suppl ( 2012-05-20), p. e14698-e14698
Kurzfassung:
e14698 Background: Expression of EGFR, Her-2 and mTOR have been linked to clinical outcomes in several solid tumors. However clinical significance of these biomarkers in gastric cancer remain unclear. This study was designed to detect the clinical implications of these three biomarkers in Turkish population. Methods: Paraffin-embedded tissue microarray blocks containing gastric cancer tissue obtained from 30 patients were constructed. Expression of mTOR, EGFR were detected by immunohistochemistry. Her-2 gene ampflication was detected by FISH. The correlation of these biomarkers to clinicopathologic features and survival of patients with gastric cancer was studied. Results: The overall rates of positive mTOR, EGFR and Her-2 status were 36.7%, 63.3% and 23.3% respectively. The EGFR expression(any grade) was significantly correlated with better OS(Overall Survival)(p=0.01). Median survival time is 34.7 months in EGFR +patients and 10.6 months in EGFR - patients. There was no significant correlation with Her-2 status and survival. But 5 of these 7 Her-2 positive patients have already took trastuzumab treatment. Also we find that her-2 pozitive tumors significantly metastasized much more frequently to liver than her-2 negative tumors.(p= 0.043) In Contrast, her-2 positive tumors significantly metastasized less commonly to periton, over, omentum as seeding than her-2 negative tumors.(p=0.009). There was no association was noted between the expression of mTOR and survival time. Conclusions: EGFR is good prognostic marker in gastric cancer patients.
Materialart:
Online-Ressource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2012.30.15_suppl.e14698
Sprache:
Englisch
Verlag:
American Society of Clinical Oncology (ASCO)
Publikationsdatum:
2012
ZDB Id:
2005181-5
Permalink